GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » DA32 Life Science Tech Acquisition Corp (NAS:DALS) » Definitions » Net Current Asset Value

DA32 Life Science Tech Acquisition (DA32 Life Science Tech Acquisition) Net Current Asset Value : $-0.25 (As of Mar. 2023)


View and export this data going back to 2021. Start your Free Trial

What is DA32 Life Science Tech Acquisition Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

DA32 Life Science Tech Acquisition's net current asset value per share for the quarter that ended in Mar. 2023 was $-0.25.

The historical rank and industry rank for DA32 Life Science Tech Acquisition's Net Current Asset Value or its related term are showing as below:

DALS's Price-to-Net-Current-Asset-Value is not ranked *
in the Diversified Financial Services industry.
Industry Median: 1.99
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

DA32 Life Science Tech Acquisition Net Current Asset Value Historical Data

The historical data trend for DA32 Life Science Tech Acquisition's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DA32 Life Science Tech Acquisition Net Current Asset Value Chart

DA32 Life Science Tech Acquisition Annual Data
Trend Dec21 Dec22
Net Current Asset Value
-0.13 -0.22

DA32 Life Science Tech Acquisition Quarterly Data
Apr21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net Current Asset Value Get a 7-Day Free Trial -0.15 -0.17 -0.19 -0.22 -0.25

Competitive Comparison of DA32 Life Science Tech Acquisition's Net Current Asset Value

For the Shell Companies subindustry, DA32 Life Science Tech Acquisition's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DA32 Life Science Tech Acquisition's Price-to-Net-Current-Asset-Value Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, DA32 Life Science Tech Acquisition's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where DA32 Life Science Tech Acquisition's Price-to-Net-Current-Asset-Value falls into.


DA32 Life Science Tech Acquisition Net Current Asset Value Calculation

DA32 Life Science Tech Acquisition's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(A: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.929-6.65-0-0)/25.65
=-0.22

DA32 Life Science Tech Acquisition's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2023 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.491-6.953-0-0)/25.65
=-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DA32 Life Science Tech Acquisition  (NAS:DALS) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.

DA32 Life Science Tech Acquisition Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of DA32 Life Science Tech Acquisition's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.

DA32 Life Science Tech Acquisition (DA32 Life Science Tech Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » DA32 Life Science Tech Acquisition Corp (NAS:DALS) » Definitions » Net Current Asset Value
Comparable Companies
GTAC FHLT SHAP QFTA SRSA PRLH CRZN TCAC OPA VHNA GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
345 Park Avenue South, 12th Floor, New York, NY, USA, 10010
Website
DA32 Life Science Tech Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Executives
Da32 Sponsor Llc 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Management Company, L.p. (series C) director, 10 percent owner, other: Director by deputization 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Arch Venture Fund Xi, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Section 32 Fund 3, Lp 10 percent owner, other: Director by Deputization 169 UNIVERSITY AVE., PALO ALTO CA 94301
Keith Crandell director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
William J Maris 10 percent owner, other: Director by Deputization 2033 SAN ELIJO AVE., #565, CARDIFF-BY-THE-SEA CA 92007
Angela Lai director 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Arch Venture Partners Xi, Llc 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xi, L.p. 10 percent owner 8755 W HIGGINS RD., SUITE 1025, CHICAGO IL 60631
Section 32 Gp 3, Llc 10 percent owner, other: Director by Deputization 171 MAIN STREET, #671, LOS ALTOS CA 94022
Steven J. Kafka director, officer: Chief Executive Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Andrew Elbardissi director 2210 FARADAY AVE #100, CARLSBAD CA 92008
Chris Wolfe officer: Chief Financial Officer 230 PARK AVENUE SOUTH, 11TH FLOOR, C/O CAPITAL Z PARTNERS, NEW YORK NY 10003
Kristina Burow 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718